**Title: Evaluating the diagnostic test accuracy of molecular xenomonitoring methods for characterising community burden of lymphatic filariasis**

**Running title (40 characters): Meta-analysis of LF xenomonitoring**

Joseph Pryce and Lisa J Reimer

Correspondence: Joseph.Pryce@lstmed.ac.uk

Department of Vector Biology

Liverpool School of Tropical Medicine

Liverpool L35QA

United Kingdom

Alternate corresponding author: Lisa.Reimer@lstmed.ac.uk

Department of Vector Biology

Liverpool School of Tropical Medicine

Liverpool L35QA

United Kingdom

Keywords:
Xenomonitoring, Lymphatic Filariasis, Mosquito

Key points:

Molecular xenomonitoring is a sensitive tool for detecting communities where LF is present. LF presence is detectable with relatively low mosquito sample sizes. The prevalence of filarial DNA in mosquitoes can be a strong predictor of human microfilaria prevalence.

**ABSTRACT**

Background

Molecular xenomonitoring (MX), the detection of pathogen DNA in mosquitoes, is a recommended approach to support lymphatic filariasis (LF) elimination efforts. Potential roles of MX include detecting presence of LF in communities and quantifying progress towards elimination of the disease. However, the relationship between MX results and human prevalence is poorly understood.

Methods

We conducted a systematic review and meta-analysis from all previously conducted studies that reported the prevalence of filarial DNA in wild-caught mosquitoes (MX rate) and the corresponding prevalence of microfilaria (mf) in humans. We calculated a pooled estimate of MX sensitivity for detecting positive communities at a range of mf prevalence values and mosquito sample sizes. We conducted a linear regression to evaluate the relationship between mf prevalence and MX rate.

Results

We identified 24 studies comprising 144 study communities. MX had an overall sensitivity of 98.3% (95% CI 41.5, 99.9%) and identified 28 positive communities that were negative in the mf survey. Low sensitivity in some studies was attributed to small mosquito sample sizes (<1,000) and very low mf prevalence (<0.25%). Human mf prevalence and mass drug administration status accounted for approximately half of the variation in MX rate (R2 = 0.49, p<0.001). Data from longitudinal studies showed that, within a given study area, there is a strong linear relationship between MX rate and mf prevalence (R2 = 0.78, p < 0.001).

Conclusion

MX shows clear potential as tool for detecting communities where LF is present and as a predictor of human mf prevalence.

**INTRODUCTION**

**Lymphatic filariasis**

There are sixty-five million people currently infected with lymphatic filariasis (LF) worldwide [1, 2], making it the second-most common vector-borne disease after malaria. The disease is associated with inflammation and dysfunction of the lymphatic system leading to severe pain and the development of chronic symptoms. More than 90% of LF cases are caused by the filarial nematode *Wuchereria bancrofti,* which is prevalent in many tropical and subtropical areas. Species from three major mosquito genera can act as vectors for *W. bancrofti: Culex pipiens quinquefasciatus* in urban areas, *Anopheles* species in rural areas of Africa and *Aedes* species in the South Pacific [3].

The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 to eliminate LF as a public health problem through mass drug administration (MDA) of preventative chemotherapy and morbidity management to alleviate suffering [4]. The drugs used in MDA do not kill the adult worms and instead target the juvenile microfilariae (mf) that are transmissible to mosquitoes. It is therefore necessary to repeat MDA for a minimum of five years, the duration of the adult worm lifespan, in order to interrupt transmission. Despite significant progress, LF has been eliminated from just 16 of the 72 previously endemic countries or territories, while a further seven countries have completed the required number of MDA campaigns [5]. The target for elimination as a public health problem was recently updated from 2020 to 2030 [6].

**LF surveillance**

Traditional LF surveillance involves screening the human population for the presence of mf, LF antigens or host antibodies [7]. If, after completing a programme of MDA, an implementation unit records either an mf prevalence of <1% or antigen prevalence of <2% at each sentinel and spot check site, a transmission assessment survey (TAS) is conducted. TAS determines whether the antigen prevalence is <2% in 6 to 7-year-old children, an indicator that transmission has been successfully interrupted and MDA can be stopped. TAS is repeated during post-MDA surveillance to ensure the interruption of transmission has been sustained [7].

These tools are not without their limitations. Antigen or antibody tests are unable to differentiate between current or prior infections. Mf detection through microscopy or PCR captures current infections but must often be conducted at night due to the nocturnal periodicity of many filarial strains. Furthermore, their sensitivity for detecting areas with very low but persistent transmission has been brought into question by a number of examples where achieving the 1% target did not lead to elimination and prevalence rebounded [8-11]. In addition, obtaining human biological samples is invasive, resource-intensive and operationally challenging at large scales [12]. Such costs may be justified when the prevalence of a disease is high, but as progress towards elimination is made and the number of cases identified per survey decreases, funding bodies and at-risk populations may lose enthusiasm for the continued use of invasive and expensive methods.

**Xenomonitoring**

While entomological surveillance for vector-borne diseases typically involves the detection of infected or infective vectors to assess disease transmission, molecular xenomonitoring (MX) involves the detection of pathogen DNA in the vector and is a proxy for the presence of the pathogen in the human population [13]. The use of MX as a surveillance tool overcomes many of the challenges associated with case surveillance as it does not rely on human blood sampling, it is relatively inexpensive, is indicative of current infections and is amenable to integrated surveillance of multiple diseases [14].

The WHO recommends that MX is incorporated into LF surveillance strategies and it is increasingly being used to lend support to programme decisions [15]. A recent meta-analysis showed that over 300,000 mosquitoes have been collected and analysed for infection [16]. However, there is no standardised approach for conducting MX surveillance.

Developing a systematic strategy for MX first requires clarification of its intended use(s). While MX methods cannot be used to identify whether individual humans are positive for LF, there are two distinct ways in which MX can support the surveillance activities of elimination programmes. First, MX may be used to determine whether LF is present in communities, particularly in areas of very low prevalence where cases may not be detected by TAS. Second, it may serve as a proxy for human prevalence and help monitor progress towards elimination. However, the sensitivity of MX to detect LF positive communities, in comparison to traditional human sampling methods, has never been evaluated. In addition, the relationship between MX rates (defined as the proportion of the mosquito population that is positive for LF DNA) and human prevalence is poorly understood. Programme decisions to stop or re-instate MDA continue to be based on specific estimates of human infection prevalence, which MX surveys are currently unable to provide.

The primary aim of this systematic review and meta-analysis is to assess the sensitivity of MX to detect areas of above zero LF prevalence and explore the factors that affect sensitivity. A secondary aim was to evaluate the relationship between mf prevalence and MX rates in areas of above zero prevalence and determine whether MX rates reflect changes in human mf prevalence.

**METHODS**

For this review and meta-analysis, we followed the Preferred Reporting Items for Systematic Reviews and Meta Analyses guidelines [17]. The review follows a protocol registered with the PROSPERO international database of prospectively registered systematic reviews in health and social care (CRD42020200351).

**Search strategy**

We searched five online bibliographic databases incorporated into EBSCO host (CINAHL Complete, MEDLINE Complete, Global Health, eBook Collection, Global Health Archive) for records published up to 9th July 2020. The search strategy is presented in Supplementary Table 1. We additionally searched the reference lists of all identified articles.

**Inclusion criteria**

Primary research studies were suitable for inclusion if they a) collected wild mosquitoes of any genus and used molecular methods to report the MX rate and b) reported the mf prevalence in the human population living in the area where mosquitoes were collected. We excluded studies where measurements of MX rate and mf prevalence were taken more than 18 months apart, or if MDA was distributed in the study area between the two time points.

**Data extraction and management**

After initial screening of the titles and abstracts of identified articles, the full texts of potentially relevant studies were read and evaluated against the inclusion criteria. Information from the included studies was extracted using prepared proformas. Each stage was completed by JP with areas of uncertainty discussed with LJR.

We extracted data on the study setting, objectives, history of MDA and other interventions, details of the primary vector and parasite species, and methods used for sampling and screening mosquito and human populations. In case of missing data, we attempted to contact study author(s) for clarification.

Where studies reported outcome data at sub-units of the overall geographical area covered, eg. individual villages within a district, we extracted information at the smallest available level. For each study area, we recorded the mf prevalence, MX rate, and binary measures of the presence or absence of filaria-positive mosquitoes and humans. Where necessary, we estimated the MX rate from the reported data using PoolScreen v2.0 [18]. Where studies screened different mosquito genera separately, we combined the survey results to determine the presence or absence of positive mosquitoes and overall MX rate.

We assessed each study’s methodological quality for answering the review objectives using a checklist adapted from the QUADAS-2 tool [19]. Studies were evaluated based on five assessment criteria: whether those interpreting mf survey results were blinded to the MX results and vice versa, the length of time between surveys, the degree to which the two sampling strategies targeted the same communities, and the continuity of methodology between sampling timepoints (longitudinal studies only). For each criteria, studies were graded as high, low or unclear risk of bias based on pre-determined specifications (Supplementary Table 2). The assessments were conducted by JP with areas of uncertainty discussed with LJR.

**Statistical analyses**

To evaluate the sensitivity of MX, we treated study areas as the unit of observation and used typical diagnostic test evaluation methods. We considered MX results as the index test and mf survey results as the reference standard to calculate the number of true positives, true negatives, false positives and false negatives in each study. We used a bivariate model utilising the *metandi* and *xtmelogit* commands in Stata version 14 to obtain a pooled estimate of the sensitivity of MX. We compared the MX sensitivity between surveys of varying mosquito sample sizes and at a range of mf prevalence values. Confidence intervals were calculated using the Wilson method [20]. We did not evaluate MX specificity due to known limitations in the sensitivity of the reference standard and strong evidence that molecular detection methods are highly specific [21]. We instead report the number of areas in which positive mosquitoes were detected despite mf surveys reporting zero positive humans.

To evaluate the relationship between mf prevalence and MX rate, we conducted a linear regression. We included covariates for primary vector genus and progress towards elimination and weighted the regression by mosquito sample size. To determine whether MX rates reflect changes in mf prevalence within a given study area, we conducted a further linear regression incorporating data from longitudinal studies only and including covariates for sampling timepoint and study site. Models were constructed using the *lm()* function in R version 3.6.2.

**RESULTS**

**Search Results**

The electronic search strategy identified a total of 1,003 records. A further three records were identified by other sources. After removal of duplicates, 335 records were screened. A total of 26 records corresponding to 24 unique studies met the inclusion criteria for the review (Figure 1) [8, 9, 22-45].

**Details of included studies**

Included studies had been conducted across a variety of geographical settings, primary vector species and elimination stages (Figure 2).

The objectives of the included studies were wide-ranging. The most common aim was to identify the presence or map the distribution of LF (12 studies). Six studies aimed to evaluate the usefulness of MX methods or compare MX results to other surveillance methods. Other objectives included measuring the impact of MDA implementation (three) or insecticide-treated net distribution (one) on LF indicators, and evaluating the field-use of novel molecular detection methods (four) or trap types (one).

All studies screened mosquito carcasses for filarial DNA. One study additionally reported the prevalence in mosquito excreta/faeces [31]. However, for consistency with the other studies, we only included the mosquito carcass MX rate in our analyses. The methods used for trapping mosquitoes, pooling, and DNA extraction and amplification varied greatly between studies. A full description of these methods is presented in Supplementary Dataset 1.

Across the 24 included studies, MX and mf survey data were available for 144 distinct areas, ranging in size from district to village level. The median number of people surveyed in each area was 509.5 (range 41 to 3,795). The median number of mosquitoes surveyed was 1,258 (range 23 to 5,280). Three studies and four study sites provided longitudinal data with a minimum of three sampling timepoints [36, 37, 41].

**Assessment of methodological quality**

Overall, there were few concerns about methodological quality across the included studies. In most studies, the mf and MX surveys were conducted within six months of one another, though two studies conducted the surveys approximately 12 to 18 months apart [8, 39]. In two studies, the MX and mf surveys did not specifically target the same communities within the study site [30, 39]. There were no concerns about the continuity of methodology in longitudinal surveys. Five studies limited their mf surveys to specific populations and the estimate of prevalence may therefore have limited applicability to the wider population. The quality assessments for each included study are provided in Supplementary Figure 1/Supplementary Table 3.

**Evaluating the sensitivity of MX methods**

Positive mosquitoes were identified in 92 of the 144 surveyed areas (63.9%). The overall sensitivity of MX for detecting mf-positive areas was 98.3% (95% CI 41.5 to 99.9%, Figure 2). In addition, MX detected positive mosquitoes in 28 areas where mf surveys failed to detect any positive individuals.

The sensitivity of MX at a range of human mf prevalence values and mosquito sample sizes is shown in Figure 3. Where the human mf prevalence was very low (<0.25%), MX surveys screening fewer than 1,000 mosquitoes had a sensitivity of 0.33 (95% CI 0.06 to 0.79). However, sensitivity increased to 0.80 (95% CI 0.38 to 1.00) when screening either 1,000-1,999 or 2,000-3,999 mosquitoes, and to 1.00 (95% CI 0.67 to 1.00) when screening 4,000-5,999 mosquitoes. At low mf prevalence levels (>0.25 to 0.5%), surveys of fewer than 1,000 mosquitoes had a sensitivity of 0.67 (95% CI 0.30 to 0.95), but all surveys screening more than 1,000 mosquitoes had a sensitivity of 1.00. Where the human mf prevalence was moderate (0.51 to 1%) or high (>1%), MX sensitivity was 1.00, regardless of the number of mosquitoes screened.

**Correlation between MX rate and mf prevalence**

Mf prevalence was significantly associated with MX rate (R2 = 0.49, p<0.001). The inclusion of primary vector genus as a covariate did not improve the predictive power of the model. The strength and slope of the relationship between MX rate and mf prevalence was lowest in study areas that had not yet received MDA and increased in areas that had made greater progress towards elimination (Figure 4A). Within each of these contexts, a large proportion of the variation between measurements of MX remained unexplained. However, data from longitudinal studies showed a strong linear relationship between MX rate and mf prevalence (R2 = 0.78, p < 0.001) (Figure 4B). Similar declines in both MX rate and mf prevalence were observed in the four included study areas over time (Supplementary Figure 2).

**DISCUSSION**

The GPELF recommends the implementation of MX alongside TAS for post-MDA surveillance, advising that 5,000-10,000 mosquitoes should be screened due to the low expected infection rate in elimination settings [15]. MX has increasingly been taken up by national LF programmes [10, 46, 47]. However, utility is limited without an understanding of the relationship between MX rates and disease prevalence. To match the evolving needs of LF programmes approaching elimination, the scope of this review was to evaluate the suitability of MX against a range of programmatic goals.

Our primary analysis shows that MX is highly sensitive for detecting filariasis presence compared to mf screening. Even when mf prevalence is low, 100% sensitivity was observed with mosquito sample sizes of 1,000 or more. When human prevalence is very low (<0.25%), samples of 4,000-6,000 mosquitoes achieved 100% sensitivity. With the ability to process mosquitoes in pools, this corresponds to approximately 200 PCR reactions. Of the two studies with <100% sensitivity, one conducted its mf and MX surveys in somewhat different locations [39] and both featured lag times of 12-18 months between MX and mf surveys. Coupled with very low mf prevalence measurements in each site (<0.3%) and the focal nature of filarial infections after MDA, these factors may explain the reduced sensitivity observed in these studies.

Our secondary analysis shows a significant relationship between MX rates and mf prevalence. The strength of this relationship was higher in areas currently undergoing or having completed MDA, compared to pre-MDA settings. In each setting, a large proportion of the variation in MX rate remains unexplained. However, analysis of a limited number of longitudinal studies revealed strong correlations between MX and mf measurements. In these four study communities, the MX rate tracked the observed declines in mf prevalence throughout MDA. This finding lends strong support for longer term monitoring using MX to track progress towards elimination.

The findings of this study should be interpreted with caution due to the limited number of MX studies that reported the corresponding mf prevalence and therefore meeting the inclusion criteria for this review. Few of the included studies primarily aimed to evaluate the accuracy of MX, and consequently the number of paired MX rate and mf prevalence observations for each study is low. As a result, the confidence intervals for our estimates of sensitivity are extremely wide. Further evidence will be required to confirm the sensitivity of MX with a high degree of certainty, particularly in areas of very low mf prevalence. The lack of consistent methodology between the studies must also be acknowledged. Besides the variables that were controlled for in our analyses (MDA status and primary vector), the included studies also employed a variety of mosquito collection methods. As these demonstrate biases towards different physiological states, MX rates measured with different strategies may differ even when the mf prevalence is constant [48]. Similarly, the different methods used for counting mf may result in different estimates of the human prevalence [49]. Included studies also differed methodologically in terms of the size of area covered, level of sampling intensity and molecular methods used for parasite detection, as well as environmentally in terms of season, presence of vector control and vector age structure. Whilst MX sensitivity appeared reliably strong despite the inconsistencies, these factors may contribute to the unexplained variation in MX rate at different levels of mf prevalence.

**Conclusions**

For MX to have applicability to current LF programme thresholds, it must accurately predict mf prevalence values below 1%, the threshold for stopping MDA. The strength of the relationship between the two variables provides reason for optimism that MX methods could be used to estimate infection rates. However, the degree of unexplained variation suggests further work is needed to understand the variables that influence MX rates before they can be used for decisions to stop MDA. This variation appears to be driven in part by methodological inconsistencies, and the explanatory power of MX would therefore be strengthened with clear normative guidance for its implementation, including collection methods, frequency, geographical scale and sample size. Furthermore, MX shows clear potential to detect positive communities where case surveillance does not, and we have shown that presence/absence detection can be achieved with relatively low mosquito sample sizes. MX could therefore play a future role in sensitively detecting resurgence in a non-invasive, sustainable way.

**Funding**

JP was supported by the Medical Research Council (N013514/) and LR gratefully acknowledges funding of the NTD Modelling Consortium by the Bill and Melinda Gates Foundation (OPP1184344)

**Acknowledgements**

We thank Marty Richardson and Peter Diggle for providing guidance on the statistical analyses conducted in this review. We also thank Edward Thomsen for insightful comments in reviewing the manuscript.

References

1. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet **2018**; 392(10159): 1789-858.

2. World Health Organization. Global vector control response 2017-2030. **2017**.

3. Cross JH. Filarial nematodes. Medical Microbiology 4th edition: University of Texas Medical Branch at Galveston, **1996**.

4. World Health Organization. Annual report on lymphatic filariasis 2002: World Health Organization, **2003**.

5. World Health Organization. Lymphatic Filariasis, Key Facts. 2020. Available at: <https://www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis>. Accessed 25 November.

6. Group NMCLF. The roadmap towards elimination of lymphatic filariasis by 2030: insights from quantitative and mathematical modelling. Gates open research **2019**; 3.

7. World Health Organization. Monitoring and epidemiological assessment of mass drug administration in the global programme to eliminate lymphatic filariasis: a manual for national elimination programmes. **2011**.

8. Subramanian S, Jambulingam P, Krishnamoorthy K, et al. Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India. PLoS neglected tropical diseases **2020**; 14(1): e0007862.

9. Rao RU, Samarasekera SD, Nagodavithana KC, et al. Reassessment of areas with persistent Lymphatic Filariasis nine years after cessation of mass drug administration in Sri Lanka. PLoS neglected tropical diseases **2017**; 11(10): e0006066.

10. Lau CL, Sheridan S, Ryan S, et al. Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration. PLoS neglected tropical diseases **2017**; 11(9): e0005914.

11. World Health Organization. The PacELF way: towards the elimination of lymphatic filariasis from the Pacific, 1999-2005. Manila: WHO Regional Office for the Western Pacific, **2006**.

12. Chu BK, Deming M, Biritwum N-K, et al. Transmission assessment surveys (TAS) to define endpoints for lymphatic filariasis mass drug administration: a multicenter evaluation. PLoS Negl Trop Dis **2013**; 7(12): e2584.

13. Pedersen EM, Stolk WA, Laney SJ, Michael E. The role of monitoring mosquito infection in the Global Programme to Eliminate Lymphatic Filariasis. Trends in parasitology **2009**; 25(7): 319-27.

14. Pi-Bansa S, Osei JHN, Joannides J, et al. Implementing a community vector collection strategy using xenomonitoring for the endgame of lymphatic filariasis elimination. Parasites & vectors **2018**; 11(1): 672.

15. World Health Organization. Lymphatic filariasis: a handbook of practical entomology for national lymphatic filariasis elimination programmes: World Health Organization, **2013**. Report No.: 9241505648.

16. Riches N, Badia-Rius X, Mzilahowa T, Kelly-Hope LA. A systematic review of alternative surveillance approaches for lymphatic filariasis in low prevalence settings: Implications for post-validation settings. PLoS neglected tropical diseases **2020**; 14(5): e0008289.

17. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS med **2009**; 6(7): e1000097.

18. Katholi CR, Unnasch TR. Important experimental parameters for determining infection rates in arthropod vectors using pool screening approaches. The American journal of tropical medicine and hygiene **2006**; 74(5): 779-85.

19. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine **2011**; 155(8): 529-36.

20. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Statistics in medicine **1998**; 17(8): 873-90.

21. Weil GJ, Ramzy RM. Diagnostic tools for filariasis elimination programs. Trends in parasitology **2007**; 23(2): 78-82.

22. Coulibaly YI, Coulibaly SY, Dolo H, et al. Dynamics of antigenemia and transmission intensity of Wuchereria bancrofti following cessation of mass drug administration in a formerly highly endemic region of Mali. Parasites & vectors **2016**; 9(1): 628.

23. Esterre P, Plichart C, Sechan Y, Nguyen NL. The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Tropical medicine & International health **2001**; 6(3): 190-5.

24. Farid HA, Hammad RE, Hassan MM, et al. Detection of Wuchereria bancrofti in mosquitoes by the polymerase chain reaction: a potentially useful tool for large-scale control programmes. Transactions of the Royal Society of Tropical Medicine and Hygiene **2001**; 95(1): 29-32.

25. Fischer P, Wibowo H, Pischke S, et al. PCR-based detection and identification of the filarial parasite Brugia timori from Alor Island, Indonesia. Annals of tropical medicine and parasitology **2002**; 96(8): 809-21.

26. Goodman DS, Orelus J-N, Roberts JM, Lammie PJ, Streit TG. PCR and mosquito dissection as tools to monitor filarial infection levels following mass treatment. Filaria Journal **2003**; 2(1): 11.

27. Helmy H, Fischer P, Farid HA, Bradley MH, Ramzy RM. Test strip detection of Wuchereria bancrofti amplified DNA in wild‐caught Culex pipiens and estimation of infection rate by a PoolScreen algorithm. Tropical Medicine & International Health **2004**; 9(1): 158-63.

28. Jones C, Ngasala B, Derua YA, et al. Lymphatic filariasis transmission in Rufiji District, southeastern Tanzania: infection status of the human population and mosquito vectors after twelve rounds of mass drug administration. Parasites & vectors **2018**; 11(1): 588.

29. Korte RL, Fontes G, Camargo JdSAA, et al. Survey of Bancroftian filariasis infection in humans and Culex mosquitoes in the western Brazilian Amazon region: implications for transmission and control. Revista da Sociedade Brasileira de Medicina Tropical **2013**; 46(2): 214-20.

30. Kouassi BL, de Souza DK, Goepogui A, et al. Assessing the presence of Wuchereria bancrofti in vector and human populations from urban communities in Conakry, Guinea. Parasites & vectors **2015**; 8(1): 492.

31. Minetti C, Pilotte N, Zulch M, et al. Field evaluation of DNA detection of human filarial and malaria parasites using mosquito excreta/feces. PLoS neglected tropical diseases **2020**; 14(4): e0008175.

32. Moustafa M, Salamah M, Thabet H, Tawfik R, Mehrez M, Hamdy D. Molecular xenomonitoring (MX) and transmission assessment survey (TAS) of lymphatic filariasis elimination in two villages, Menoufyia Governorate, Egypt. European Journal of Clinical Microbiology & Infectious Diseases **2017**; 36(7): 1143-50.

33. Opoku M, Minetti C, Kartey-Attipoe WD, et al. An assessment of mosquito collection techniques for xenomonitoring of anopheline-transmitted Lymphatic Filariasis in Ghana. Parasitology **2018**; 145(13): 1783-91.

34. Owusu IO, de Souza DK, Anto F, et al. Evaluation of human and mosquito based diagnostic tools for defining endpoints for elimination of Anopheles transmitted lymphatic filariasis in Ghana. Transactions of the Royal Society of Tropical Medicine and Hygiene **2015**; 109(10): 628-35.

35. Pam DD, de Souza DK, D'Souza S, et al. Is mass drug administration against lymphatic filariasis required in urban settings? The experience in Kano, Nigeria. PLoS neglected tropical diseases **2017**; 11(10): e0006004.

36. Ramzy RM, El Setouhy M, Helmy H, et al. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. The Lancet **2006**; 367(9515): 992-9.

37. Rao RU, Nagodavithana KC, Samarasekera SD, et al. A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration. PLoS Negl Trop Dis **2014**; 8(11): e3281.

38. Rao RU, Samarasekera SD, Nagodavithana KC, et al. Comprehensive assessment of a hotspot with persistent bancroftian filariasis in coastal Sri Lanka. The American Journal of Tropical Medicine and Hygiene **2018**; 99(3): 735-42.

39. Rao RU, Samarasekera SD, Nagodavithana KC, et al. Programmatic use of molecular xenomonitoring at the level of evaluation units to assess persistence of lymphatic filariasis in Sri Lanka. PLoS neglected tropical diseases **2016**; 10(5): e0004722.

40. Reimer LJ, Thomsen EK, Tisch DJ, et al. Insecticidal bed nets and filariasis transmission in Papua New Guinea. New England Journal of Medicine **2013**; 369(8): 745-53.

41. Weil GJ, Kastens W, Susapu M, et al. The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl Trop Dis **2008**; 2(12): e344.

42. Wijegunawardana N, Gunawardene YS, Manamperi A, Senarathne H, Abeyewickreme W. Geographic information system (GIS) mapping of lymphatic filariasis endemic areas of Gampaha District, Sri Lanka based on epidemiological and entomological screening. Southeast Asian Journal of Tropical Medicineand Public Health **2012**; 43(3): 557.

43. Yokoly FN, Zahouli JB, Méite A, et al. Low transmission of Wuchereria bancrofti in cross-border districts of Côte d’Ivoire: A great step towards lymphatic filariasis elimination in West Africa. PloS one **2020**; 15(4): e0231541.

44. Supali T, Wibowo H, Rückert P, et al. High prevalence of Brugia timori infection in the highland of Alor Island, Indonesia. The American journal of tropical medicine and hygiene **2002**; 66(5): 560-5.

45. Farid HA, Morsy ZS, Helmy H, Ramzy RM, El Setouhy M, Weil GJ. A critical appraisal of molecular xenomonitoring as a tool for assessing progress toward elimination of Lymphatic Filariasis. The American journal of tropical medicine and hygiene **2007**; 77(4): 593-600.

46. Swaminathan S, Purushothaman J, Chu BK, et al. Application of a household-based molecular xenomonitoring strategy to evaluate the lymphatic filariasis elimination program in Tamil Nadu, India. PLOS Neglected Tropical Diseases **2017**; 11(4): e0005519.

47. Dorkenoo MA, de Souza DK, Apetogbo Y, et al. Molecular xenomonitoring for post-validation surveillance of lymphatic filariasis in Togo: no evidence for active transmission. Parasites & vectors **2018**; 11(1): 52.

48. Irish SR, Stevens WM, Derua YA, Walker T, Cameron MM. Comparison of methods for xenomonitoring in vectors of lymphatic filariasis in northeastern Tanzania. The American journal of tropical medicine and hygiene **2015**; 93(5): 983-9.

49. Melchers NVV, Coffeng LE, de Vlas SJ, Stolk WA. Standardisation of lymphatic filariasis microfilaraemia prevalence estimates based on different diagnostic methods: a systematic review and meta-analysis. Parasites & Vectors **2020**; 13(1): 1-9.

**Figure Legends**

Figure 1. Results of the search and reasons for exclusion of studies.

Figure 2. Forest plot summarising the study details and the sensitivity of MX for detecting communities that were positive for LF as determined by microfilaria surveys. The pooled estimate of sensitivity is indicated by the black square. Abbreviations: MDA (Mass Drug Administration), TP (True Positives), FP (False Positives), FN (False Negatives), TN (True Negatives), PS (Preliminary Survey).

Figure 3. MX sensitivity for detecting communities that are positive for LF (as determined by microfilaria surveys) at a range of microfilaria prevalence and with varying mosquito sample size

Figure 4. A: Linear regression models demonstrating the relationship between human mf prevalence and MX rate in a variety of elimination phases. B: Linear regression model demonstrating the relationship between human mf prevalence and MX rate when consistent methods are used for sampling and screening of humans and mosquitoes (using data provided by longitudinal studies only)